Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Free association

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    639 result(s) found for: Free association. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005792-12 Sponsor Protocol Number: GOIRC-06-2020 Start Date*: 2022-04-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007698-22 Sponsor Protocol Number: R2-CHOP Start Date*: 2008-07-10
    Sponsor Name:GELARC
    Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA
    Medical condition: B cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002991-15 Sponsor Protocol Number: SOLTI-1804 Start Date*: 2019-11-04
    Sponsor Name:SOLTI
    Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302
    Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004126-13 Sponsor Protocol Number: CaPture Start Date*: 2020-10-06
    Sponsor Name:University Leipzig
    Full Title: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors
    Medical condition: Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004874-42 Sponsor Protocol Number: TRAFO001 Start Date*: 2009-02-06
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M...
    Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005756-37 Sponsor Protocol Number: CONTENTSS Start Date*: 2021-11-02
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la
    Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock
    Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10021881 - Infections and infestations 10040089 Septicemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003778-29 Sponsor Protocol Number: CIFRA Start Date*: 2019-03-06
    Sponsor Name:Istituto Nazionale Tumori G. Pascale
    Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V
    Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003835-31 Sponsor Protocol Number: IB2018-04 Start Date*: 2021-09-28
    Sponsor Name:Institut Bergonié
    Full Title: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study
    Medical condition: Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024190 Leiomyosarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003542-21 Sponsor Protocol Number: ALADDIN Start Date*: 2022-02-28
    Sponsor Name:ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie
    Full Title: Evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
    Medical condition: Prostate cancer with pelvic lymph nodes metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005272-34 Sponsor Protocol Number: 42703 Start Date*: 2013-01-28
    Sponsor Name:Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose NVALT
    Full Title: Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment.
    Medical condition: Non small cell lung cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001316-47 Sponsor Protocol Number: ML18580 Start Date*: 2005-07-05
    Sponsor Name:Turku University Central Hospital
    Full Title: Bevacizumab (Avastin™), dacarbazine and interferon α-2a (Roferon-A; IFN α-2a ) combination as a first-line therapy in patients with locally advancing or metastatic melanoma
    Medical condition: Patients with histologically confirmed metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-001918-25 Sponsor Protocol Number: 111714 Start Date*: 2009-01-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and prog...
    Medical condition: Patients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004010-34 Sponsor Protocol Number: ClaTBI/2019 Start Date*: 2020-05-18
    Sponsor Name:Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach
    Full Title: Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukem...
    Medical condition: Accute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003768-30 Sponsor Protocol Number: IEO906 Start Date*: 2019-11-12
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors
    Medical condition: Pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003657-24 Sponsor Protocol Number: BRIL06 Start Date*: 2006-09-06
    Sponsor Name:GIMURELL
    Full Title: A PHASE II MULTICENTER NON-RANDOMIZED STUDY TO ASSESS SAFETY, TOXICITY AND CLINICAL ACTIVITY OF THE ASSOCIATION OF BORTEZOMID VELCADE WITH RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON FOLLICULAR...
    Medical condition: relapsed non follicular non-Hodgkin s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029621 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002625-35 Sponsor Protocol Number: CALGB80802 Start Date*: 2013-09-23
    Sponsor Name:All Ireland Co-operative Oncology Research Group (ICORG)
    Full Title: Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)
    Medical condition: Advanced or Metastatic Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001114-19 Sponsor Protocol Number: IB2022-01 Start Date*: 2023-04-03
    Sponsor Name:Institut Bergonié
    Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer
    Medical condition: platinum sensitive extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002332-81 Sponsor Protocol Number: IB2019-03 Start Date*: 2019-11-08
    Sponsor Name:Institut Bergonié
    Full Title: CombinatiOn of NivolumAb plus Relatlimab in patients with Advanced or metastatic soft-tissue Sarcoma: a proof-of-concept randomized phase II study
    Medical condition: Advanced soft-tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001907-33 Sponsor Protocol Number: S2472 Start Date*: 2022-07-21
    Sponsor Name:Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation
    Full Title: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere™ followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere™ Alon...
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2017-004512-19 Sponsor Protocol Number: UC-0160/1717 Start Date*: 2018-10-09
    Sponsor Name:UNICANCER
    Full Title: An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-...
    Medical condition: High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 17:59:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA